New drug combo for non-GCB diffuse large B-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three targeted drugs (polatuzumab vedotin, zanubrutinib, and R-CHP) for people newly diagnosed with a specific subtype of DLBCL called non-GCB. The goal is to see if this powerful mix can work better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a certain type of DLBCL called non-GCB that has spread outside the lymph nodes.
- You need at least one tumor that can be measured (at least 1.5 cm in a node or 1 cm outside a node).
- Your daily activities should be fairly good (ECOG score 0 to 2).
- Your heart, kidneys, and liver must work well enough (heart ejection fraction of 50% or more, adequate kidney and liver function).
- Your blood counts must be in a safe range (platelets at least 50,000, hemoglobin at least 8, neutrophils at least 1,000).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This study tests a combination of five drugs (including a targeted therapy called polatuzumab vedotin) for patients with a specific type of aggressive lymphoma (DLBCL) that has never been treated before. The goal is to see if this combination works better and is safe for certain subtypes of this cancer.
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
This trial tests a new combination of drugs for a certain type of lymphoma (non-GCB DLBCL). The drugs are pirtobrutinib (a targeted pill) plus a standard chemotherapy regimen called Pola-R-CHP. The goal is to see if adding this targeted therapy improves outcomes for people with this specific subtype.
This trial tests a combination of targeted drugs for people with a type of lymphoma (DLBCL) that has come back or not responded after previous treatment with a BTK inhibitor. The goal is to see if adding a drug called pirtobrutinib to standard chemotherapy helps control the cancer.
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
Hear when a new Safety Issues trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.